Skip header and navigation
Did you mean topic:"colitic"? Also try colitic.

Narrow By

2 records – page 1 of 1.

5-Aminosalicylate (5-ASA)

https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1483
Available Online
View Pamphlet
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Crohn Disease - drug therapy
Colitis - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Colitis
Abstract
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
Responsibility
Prepared by: Jennifer Stewart, RN; Gastroenterology
Prepared by: Kaleigh MacIsaac, B.ScPharm; Gastroenterology
Revised by: Phyllis Durning, RN
Revised by: Alison Harding, B.Sc.
Pamphlet Number
1483
Less detail

Vedolizumab (Entyvio) therapy

https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1623
Available Online
View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when und…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (11 p.) : digital, PDF file
Subjects (MeSH)
Gastrointestinal Agents
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy
Subjects (LCSH)
Gastrointestinal agents
Ulcerative colitis
Crohn's disease
Specialty
Medications
Abstract
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1623
Less detail